Source: Virtual Congress 2020 – Scientific advances in airway pharmacology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Pinkerton (London, United Kingdom), B. Dekkak (London, United Kingdom), D. Zervas (London, United Kingdom), T. Markou (London, United Kingdom), A. Borde (Gothenburg, Sweden), A. Cavallin (Gothenburg, Sweden), T. Ericsson (Gothenburg, Sweden), R. Hendrickx (Gothenburg, Sweden), A. Aurell Holmberg (Gothenburg, Sweden), J. Steele (Gothenburg, Sweden), M. Belvisi (Gothenburg, Sweden), M. Birrell (Gothenburg, Sweden). Profiling the impact of two JAK inhibitors in a pre-clinical model of allergic asthma. 3302

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of a novel PI3Kd inhibitor, DS-1515 in animal models of asthma Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018 Inhibition of Pim1 kinase, new therapeutic approach in virus-induced asthma exacerbations Source: Eur Respir J 2016; 47: 783-791 Year: 2016 Anti-inflammatory effects of the JAK inhibitor tofacitinib in two murine house dust mite -driven models of asthma. Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018 Characterisation of a chronic pre-clinical model of allergic asthma Source: International Congress 2018 – Studies on the mechanisms underlying airway disease Year: 2018 Roles of PI3k pan-inhibitors and PI3k-d inhibitors in allergic lung inflammation: systematic review and a meta-analysis Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 JAK inhibitors overcome corticosteroid insensitivity in COPD Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011 Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 The effects of anti-IL-13 on allergen-induced responses; a Phase II study in subjects with mild atopic asthma - The allergen challenge as a model of allergic asthma for proof-of-concept studies Source: Annual Congress 2008 - Clinical trial - The effects of an anti-IL-13 human monoclonal antibody, IMA-638, on allergen-induced airway responses in subjects with mild atopic asthma Year: 2008 Prediction of human lung PK for AZD7624, an inhaled P38 inhibitor for the treatment of COPD Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Anti IL-17 with or without Rho kinase inhibitor in mice with chronic allergic pulmonary inflammation Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies Year: 2009 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment Year: 2009 Inhaled JAK inhibitor GDC-4379 reduces FeNO in patients with mild asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021 The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019 Specific NFKappaB and Rho-Quinase inhibitors compared to corticosteroid in asthma model in mice Source: International Congress 2017 – Translational studies of lung disease Year: 2017 A novel evaluation of the impact of severe allergic asthma in children: The family perspective Source: Annual Congress 2010 - Quality of life, asthma control and monitoring childhood asthma Year: 2010